Literature DB >> 14713543

Predominant K-ras codon 12 G --> A transition in chemically induced lung neoplasms in B6C3F1 mice.

Thai-Vu T Ton1, Hue-Hua L Hong, Colleen H Anna, June K Dunnick, Theodora R Devereux, Robert C Sills, Yongbaek Kim.   

Abstract

Based on long-term toxicity and carcinogenicity studies in B6C3F1 mice conducted by the National Toxicology Program, 2,2-Bis(bromomethyl)-1,3-propanediol (BMP) and tetranitromethane (TNM) have been identified as carcinogens. Following 2 yr of exposure to 312, 625, or 1,250 ppm BMP in feed, or exposure to 0.5 or 2 ppm TNM by inhalation, increased incidences of lung neoplasms were observed in B6C3F1 mice at all exposure concentrations compared to unexposed mice. The present study characterizes genetic alterations in the K-ras protooncogene in BMP- and TNM-induced lung neoplasms, respectively, and compares the findings to spontaneous lung neoplasms from corresponding control mice. The frequencies of the K-ras mutations were 57% (29/51) in BMP-induced lung neoplasms compared to 15% (3/20) in lung neoplasms from dosed feed control mice, and 54% (14/26) in TNM-induced lung neoplasms compared to 60% (3/5) in lung neoplasms from inhalation control mice. G --> A transitions at the second base of the K-ras codon 12 (GGT --> GAT) were the most frequent pattern of K-ras mutations identified in BMP-induced (20/29) and TNM-induced lung neoplasms (13/14), which differed from the mutational patterns identified in the lung neoplasms from unexposed control mice. These results indicate that mutations in the K-ras gene are involved in B6C3F1 lung carcinogenesis following BMP- and TNM-exposure, and the high frequency and specificity of the ras mutation profile in lung neoplasms (G --> A transition) may be due to in vivo genotoxicity by the parent compounds or their metabolites.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14713543     DOI: 10.1080/01926230490260682

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  2 in total

1.  Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis.

Authors:  Laura P Stabile; Mary E Rothstein; Phouthone Keohavong; Jide Jin; Jinling Yin; Stephanie R Land; Sanja Dacic; The Minh Luong; K Jin Kim; Austin M Dulak; Jill M Siegfried
Journal:  Mol Cancer Ther       Date:  2008-07       Impact factor: 6.261

2.  Commemorating Toxicology at the National Institute of Environmental Health Sciences on the Occasion of Its 50th Anniversary.

Authors:  John R Bucher; Linda S Birnbaum
Journal:  Environ Health Perspect       Date:  2016-11-01       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.